Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 16/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18692578 | 0.91 | CFTR (0.44) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18717668 | 0.87 | CFTR (0.43) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18692687 | 0.87 | CFTR (0.57) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18693296 | 0.86 | CFTR (0.60) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18692654 | 0.83 | CFTR (0.64) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18692970 | 0.80 | CFTR (0.64) | CFTR | |
| SCHEMBL18692367 | 0.79 | CFTR (0.56) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18693139 | 0.79 | CFTR (0.52) | CFTRSIGMAR1CYP2C9HRH1TMEM97 | |
| SCHEMBL18692353 | 0.78 | CFTR (0.57) | CFTRHRH3 | |
| SCHEMBL18693430 | 0.77 | CFTR (0.51) | CFTRSIGMAR1CYP2C9HRH1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | claimed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | AbbVie S.à.r.l. (LU) | 2019-04-16 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| WO-2017060874-A1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE S.Á.R.L (LU) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101405-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885SIGMAR1 360/4885CYP2C9 1134/4885 |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CFTR 1/4885SIGMAR1 1529/4885CYP2C9 656/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | CFTR 1/4885SIGMAR1 420/4885CYP2C9 1346/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | CFTR 1/4885SIGMAR1 360/4885CYP2C9 1134/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | CFTR 1/4885SIGMAR1 420/4885CYP2C9 1346/4885 |
| US-10259810-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, P2RY1, P2RX5 | CFTR 1/4885SIGMAR1 360/4885CYP2C9 1134/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885SIGMAR1 3298/4885CYP2C9 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.